Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toru Arano

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
The American Journal of Gastroenterology|December 14, 2011
Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factorsShuichiro Shiina, Ryosuke Tateishi, Toru Arano, et al.
World Journal of Gastroenterology|April 12, 2012
Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastographyRyota Masuzaki, Ryosuke Tateishi, Haruhiko Yoshida, et al.
Journal of Gastroenterology and Hepatology|August 30, 2014
Impact of serum levels of interleukin-6 and adiponectin on all-cause, liver-related, and liver-unrelated mortality in chronic hepatitis C patientsHayato Nakagawa, Naoto Fujiwara, Ryosuke Tateishi, et al.
International Journal of Cancer|December 21, 2010
Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patientsToru Arano, Hayato Nakagawa, Ryosuke Tateishi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 17, 2010
Intrahepatic bile duct dilatation after percutaneous radiofrequency ablation for hepatocellular carcinoma: impact on patient's prognosisYuji Kondo, Shuichiro Shiina, Ryosuke Tateishi, et al.
The American Journal of Gastroenterology|May 1, 2013
CT with hepatic arterioportography as a pretreatment examination for hepatocellular carcinoma patients: a randomized controlled trialTakamasa Ohki, Ryosuke Tateishi, Masaaki Akahane, et al.
Journal of Gastroenterology|March 23, 2012
Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinomaKoji Uchino, Shuntaro Obi, Ryosuke Tateishi, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
The American Journal of Gastroenterology|December 14, 2011
Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factorsShuichiro Shiina, Ryosuke Tateishi, Toru Arano, et al.
World Journal of Gastroenterology|April 12, 2012
Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastographyRyota Masuzaki, Ryosuke Tateishi, Haruhiko Yoshida, et al.
Journal of Gastroenterology and Hepatology|August 30, 2014
Impact of serum levels of interleukin-6 and adiponectin on all-cause, liver-related, and liver-unrelated mortality in chronic hepatitis C patientsHayato Nakagawa, Naoto Fujiwara, Ryosuke Tateishi, et al.
International Journal of Cancer|December 21, 2010
Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patientsToru Arano, Hayato Nakagawa, Ryosuke Tateishi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 17, 2010
Intrahepatic bile duct dilatation after percutaneous radiofrequency ablation for hepatocellular carcinoma: impact on patient's prognosisYuji Kondo, Shuichiro Shiina, Ryosuke Tateishi, et al.
The American Journal of Gastroenterology|May 1, 2013
CT with hepatic arterioportography as a pretreatment examination for hepatocellular carcinoma patients: a randomized controlled trialTakamasa Ohki, Ryosuke Tateishi, Masaaki Akahane, et al.
Journal of Gastroenterology|March 23, 2012
Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinomaKoji Uchino, Shuntaro Obi, Ryosuke Tateishi, et al.
Pageof 2